Metsera, Inc. Amends Merger Agreement with Pfizer Inc.

Summary

On November 7, 2025, Metsera, Inc. announced an amendment to its previously disclosed merger agreement with Pfizer Inc. The amendment increases the upfront cash consideration from $47.50 to $65.60 per share and adjusts the contingent value rights (CVR) from up to $22.50 to up to $20.65 per share. The amendment also modifies certain financial terms and milestones related to the merger. Metsera issued a press release announcing the signing of the amendment.